Strong product sales and key progress in pipeline catalysts LUND, Sweden, April 24, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced its interim report for January-March 2025. Peter Nicklin, Chairman of the Board, Hansa Biopharma...
Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results )
Also on site :
- Faith leaders challenge Texas law requiring Ten Commandments in classrooms
- Kremlin reveals how Putin will take part in BRICS summit
- 'M3GAN’ Star, 37, Details ‘Profoundly Scary’ Experience She Encountered: 'Huge Trauma'